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Martino Introna, Alice Pievani, Gianmaria Borleri, Chiara Capelli, Alessandra Algarotti,
Caterina Mico`, Anna Grassi, Elena Oldani, Josee Golay, Alessandro RambaldiFive patients with aggressive acute leukemias who had relapsed after cord blood transplantation were treated
with cord blood derived cytokine-induced killer (CIK) cells. These were obtained by ex vivo expansion, using
as starting material the washouts of the cord blood units, left over at the end of the transplant. We did not
observe any acute or delayed adverse event, and observed 1 partial response in 1 patient concomitantly with
the development of acute grade III graft-versus-host disease (GVHD). These observations show the rela-
tively low toxicity of cord blood-derived CIK cells and, more importantly, the feasibility of this immunother-
apy program for patients who could not otherwise benefit from donor lymphocyte infusions.
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Mesenchymal stromal cells, GVHDINTRODUCTION
Cord blood transplantation (CBT) is receiving
increasing interest in the adult clinical setting [1]. De-
spite an acceptable engraftment rate, high relapse
incidence remains a major problem [2–4]. Moreover,
salvage treatment options based on adoptive immuno-
therapy, such as donor lymphocyte infusions (DLIs),
are not applicable because the donor is unavailable.
We have tried to improve the therapeutic prospective
of CBT by investigating the possibility of using cord
blood (CB)-derived cytokine-induced killer (CIK) cells
expanded from the washouts of the CB unit bags [5] to
treat CBT patients at relapse. CIK cells are CD8 effec-
tor memory T cells that have acquired in vitro natural
killer (NK)-like nonspecific cytotoxicity [6,7]. They
home to tumors in vivo and show little graft-versus-
host disease (GVHD) in mice [7,8]. In our previous
phase I study, peripheral blood-derived CIK cells of do-
nor origin have been administered to HLA-matched
recipients relapsed after allogeneic hematopoietic stem
cell transplantation (HSCT) [9]. Indeed, this study
demonstrated some clinical activity in 5 of 11 patients
with negligible acute toxicity [9]. We have thereforeUSC Hematology, Ospedali Riuniti Bergamo, Italy.
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6/j.bbmt.2010.05.015planned to expand CIK cells from all CB available
from CBT patients in the last 2 years to treat
leukemia-relapsed patients. We show here that this
approach is feasible in Good Manufacturing Practice
(GMP) conditions, and we report the first 5 patients
treated with these cells in our department.METHODS
Cells and Cultures
CIK cells were prepared under GMP conditions.
Briefly, mononuclear cells obtained from umbilical
CB bag washouts were cultured in X-VIVO 15
serum-free medium (Lonza, Verviers, Belgium). A
total of 1000 U/mL rhIFN-g (Boehringer Ingelheim,
Vienna, Austria) was added at day 0, 50 ng/mL OKT-
3 mAb (Janssen Cilag, Schaffhausen, Switzerland), and
500 IU/mL rhIL-2 (Chiron Corp., Uxbridge, UK) on
day 1. After 21 to 28 days of expansion in rhIL2, cells
were cryopreserved in human plasma obtained from
the hospital transfusion center and 10% DMSO
(WAK-Chemie Medica GmbH, Steinbach, Germany).
Cell Characterization
For phenotypic analysis of CIK cells fluorescein-
labeled monoclonal anti-CD3 antibody and
phycoerythrin-labeled anti-CD56 antibody were used
(both from Becton Dickinson, San Jose, CA, USA).
Stained cells were analyzed on a FACScan instrument
(Becton Dickinson). In vitro cytotoxicity of CIK culture
preparations against the K562 cell line or against puri-
fied patients’ blasts, whenever available, was evaluated1603
1604 Biol Blood Marrow Transplant 16:1603-1607, 2010M. Introna et al.by using a standard Calcein-AM release assay at
different effector:target ratios.
Chimerism Analysis and NPM1 Evaluation
Genomic DNA was extracted from peripheral
blood CD3 positive and negative fractions using a com-
mercial kit (Genera Systems, Inc., Minneapolis, MN,
USA). DNA was amplified using the Amplest Identi-
fier Kit (Applied Biosystems, Foster City, CA, USA).
Electrophoresis, detection of products and genotyping
were carried out on the ABI PRISM 310 Genetic An-
alyzer using the ABI PRISM 310 Data Collection and
GeneMapperID softwares (Applied Biosystems).
For NPM1 mutation analysis, genomic DNA was
amplified and sequenced as previously described [10].
NPM1 type A expression level was performed by real-
time polymerase chain reaction (PCR) as described [11].RESULTS
We recently reported that the washouts of the
empty CB units are sufficient to expand CIK cells in
clinically relevant numbers using a standardized proto-
col [5] and in strict adherence to GMP regulation in
our approved Cell Factory (AIFA authorization no.
aM-198/2008). Production of CIK cells was authorized
by ISS (Prot 14/06/2005-0030257) and by AIFA (14/
04/2009) for the treatment of patients relapsed after
allogeneic bone marrow transplantation. For each
patient the Ethical Committee authorized the treat-
ment on a compassionate basis. We report here on 5
consecutive patients who relapsed after CBT and
were treated with CB-derived CIK (CB-CIK) cells.
The in vitro culture allowed expansion of
CD31CD561 CIK cells. A mean absolute number ofFigure 1. Characterization of CB-CIK cultures. (A) Expansion data of CIK cult
of CD31, CD31/CD561 (CIK), CD31/CD562, and CD32/CD561 cells obtain
(B) In vitro cytotoxic activity by CB-CIK cultures. CIK cells prepared for patien
indicated E:T ratios and target cell lysis calculated. The results are the meansCD31/CD561 CIK cells of 252  106 (range: 34-
507  106), and mean CD31/CD561 percentage of
53.2 6 24.5% (data not shown and Figure 1A) were
obtained, consistent with our preclinical experience
[5]. The remaining cells were CD31/CD562 (29.9 6
11.6%) and CD32/CD561 (17.26 15.6%) (Figure 1A).
Distribution of naı¨ve, central memory, effector mem-
ory, and RA-positive EM and memory subsets was
comparable in the CD31/CD561 and CD31/CD562
subpopulations ([6], and data not shown). In 3 cases
(#2, #3, and #5) we could study in vitro cytotoxicity
of CIK preparations at the end of culture, demonstrat-
ing significant cytotoxic activity against both K562
cells and the freshly isolated leukemic blasts of the
recipient (purity.95%), with a mean target cell killing
of 80%6 7.8% and 62%6 8.8%, respectively, and an
effector to target ratio of 30:1 (Figure 1B). Comparable
cytotoxicity was also measured against fully mismatched
leukemic blasts ([5] and data not shown).
As detailed in Table 1, the median age of patients (4
males, 1 female) was 33 years (range: 18-50 years). Four
patients had acute myelogenous leukemia (AML) and 1
T cell acute lymphoblastic leukemia (T-ALL). Three
patients had a refractory disease at transplant and 2
were in second complete remission. In 2 cases a myeloa-
blative, total body irradiation (TBI)-based condition-
ing regimen was applied, whereas 3 patients received
a reduced toxicity program. The HLA matching was
4 of 6 in 3 cases and 5 of 6 in 2 cases. Four patients
relapsed after a median of 91 days (range: 68-245
days) and 1 suffered early progression. In 3 cases,
chemotherapy was given before CIK administration
to ensure appropriate cytoreduction. Only 1 CB-CIK
cell infusion was given to 3 patients, whereas 2 patients
received 3 and 4 infusions, respectively. Frozen CIK
cells were given after a median of 7 days (range: 1-7)ures from cord blood. The absolute numbers and percentage distribution
ed at the start and at end of CB-CIK cultures for all 5 patients are shown.
ts #2, #3, and #5 were tested against K562 or fresh leukemic blasts at the
and standard deviations of 3 independent experiments.
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Biol Blood Marrow Transplant 16:1603-1607, 2010 1605CIK Cells Therapy after Cord Blood Transplantationafter leukemia relapse. A median of 1.5  106/kg CIK
cells (range: 1-8  106/kg, with a viability superior to
90% as determined at thawing) were infused. The pa-
tients were not pharmacologically immunosuppressed
at the time of CIK infusion. No acute toxicity was ob-
served in agreement with our previous phase I data [9].
Acute intestinal grade III GVHD was observed in 1
case (#3), which is also the patient who showed some
clinical response (see below). All other patients pro-
gressed and died of disease after a median of 84 days
(range: 29-241) from the first CIK administration.
Case #3 is detailed in Figure 2. At day 152 after
CBT, this patient showed 70% myelogenous blasts in
the peripheral blood, so that Cyclosporine-A was im-
mediately withdrawn and Cytarabine (200 mg/day)
given for 5 days. CIK cells (1  106/kg) together with
a single dose of 6  106 U of rhIL-2 were given the
day after the end of chemotherapy. At day168, we reg-
istered the appearance of cutaneous gastrointestinal
and hepatic grade III aGVHD, as exemplified by the
bilirubin levels (Figure 2). At day 171, a clearance of
leukemic blasts was documented in the peripheral
blood. At day184 the molecular evaluation of hemato-
poietic chimerism showed 100% donor origin, and the
evaluation of minimal residual disease by PCR analysis
of the NPM1 mutation [11], revealed that leukemic
cells were below 1%.
Despite full steroid treatment, hepatic GVHD
worsened and required a second line of treatment. To
avoid the use of further immunosuppressant drugs, we
decided to offer mesenchymal stromal cells (MSC),
which have been suggested to be effective second line
treatment [12,13] and are produced in our Cell
Factory for this specific clinical use (Eudract number
2008-007869-23; authorization ISS prot. 13/05/
2009). Two third-party MSC infusions were adminis-
tered to the patient who showed a rapid clinical
response of the skin, hepatic, and gastrointestinal symp-
toms (Figure 2). Unfortunately, a leukemia relapse
rapidly occurred and the patient died at day1117.DISCUSSION
We believe this report is the first demonstration of
adoptive cell transfer in UCB transplanted patients fol-
lowing leukemia relapse. We have demonstrated the
feasibility of the program and its relatively low toxicity.
CIK cells that show cytotoxicity in vitro against the
leukemic blasts of the recipient can be prepared in clin-
ically significant numbers in GMP conditions. We
cannot claim that CIK cells represent a rescue therapy
for patients relapsed following CBT, but this report
shows that viable T cells can be recovered from the
washouts of the CB unit, expanded in vitro, and used
for immunotherapy programs in such patients. It is in-
triguing that, as in our previous phase I study in bone
Figure 2. Clinical response to therapy of AML patient #3. The results obtained with patient #3 are shown. The x-axis shows the days from transplan-
tation. In the upper panel thewhite blood cell (WBC) and platelet (PLT) counts as well as the bilirubin values are shown. In the lower panel theCD3, CD8,
and CD16 counts are reported. The vertical bars represent molecular chimerism detection in 2 peripheral blood (PB) samples evaluated on the myeloid
(M) as well as lymphoid (L) component. Major pharmacological treatments are also indicated with arrows and lines in the upper part of the figure.
1606 Biol Blood Marrow Transplant 16:1603-1607, 2010M. Introna et al.marrow-transplanted patients, the best clinical re-
sponse has been observed here concomitantly with
the development of aGVHD. This information under-
lines the T cell nature of CIK cells, despite preclinical
data [7,14]. Nonetheless, the exact mechanism that
leads to GVHD in vivo is still unclear. Indeed,
a major DRB1 mismatch was present in 3 patients
(#3, #4, and #5), but only 1 developed GVHD. The
comparison is even more striking if one considers
that the T cell precursors of CIK cells are in this
case naı¨ve. Finally, the observation of the timing of
relapse and CIK administration may now suggest the
favoring of a more rapid preemptive form of therapy.ACKNOWLEDGMENTS
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